JP2005502319A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502319A5
JP2005502319A5 JP2002579898A JP2002579898A JP2005502319A5 JP 2005502319 A5 JP2005502319 A5 JP 2005502319A5 JP 2002579898 A JP2002579898 A JP 2002579898A JP 2002579898 A JP2002579898 A JP 2002579898A JP 2005502319 A5 JP2005502319 A5 JP 2005502319A5
Authority
JP
Japan
Prior art keywords
antibody
polypeptide
dna
fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002579898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502319A (ja
JP4370428B2 (ja
Filing date
Publication date
Priority claimed from FR0104712A external-priority patent/FR2823221B1/fr
Application filed filed Critical
Publication of JP2005502319A publication Critical patent/JP2005502319A/ja
Publication of JP2005502319A5 publication Critical patent/JP2005502319A5/ja
Application granted granted Critical
Publication of JP4370428B2 publication Critical patent/JP4370428B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

JP2002579898A 2001-04-06 2002-04-05 疾患関連タンパク質 Expired - Lifetime JP4370428B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009050689A Division JP4571695B2 (ja) 2001-04-06 2009-03-04 疾患関連タンパク質

Publications (3)

Publication Number Publication Date
JP2005502319A JP2005502319A (ja) 2005-01-27
JP2005502319A5 true JP2005502319A5 (https=) 2009-06-18
JP4370428B2 JP4370428B2 (ja) 2009-11-25

Family

ID=8862037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002579898A Expired - Lifetime JP4370428B2 (ja) 2001-04-06 2002-04-05 疾患関連タンパク質
JP2009050689A Expired - Lifetime JP4571695B2 (ja) 2001-04-06 2009-03-04 疾患関連タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009050689A Expired - Lifetime JP4571695B2 (ja) 2001-04-06 2009-03-04 疾患関連タンパク質

Country Status (22)

Country Link
US (6) US7795387B2 (https=)
EP (1) EP1379657B1 (https=)
JP (2) JP4370428B2 (https=)
KR (1) KR100913258B1 (https=)
CN (1) CN1529753B (https=)
AU (1) AU2002312794B8 (https=)
BR (1) BRPI0208870B8 (https=)
CA (1) CA2443345C (https=)
CZ (1) CZ305800B6 (https=)
EC (1) ECSP024345A (https=)
ES (1) ES2597835T3 (https=)
FR (1) FR2823221B1 (https=)
HU (1) HU226307B1 (https=)
IL (3) IL158013A0 (https=)
MX (1) MXPA03009114A (https=)
NO (1) NO331277B1 (https=)
NZ (1) NZ528376A (https=)
PL (1) PL213658B1 (https=)
RU (1) RU2384586C2 (https=)
SK (1) SK288465B6 (https=)
WO (1) WO2002081513A2 (https=)
ZA (1) ZA200307403B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
WO2009146183A1 (en) * 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
WO2010029130A1 (en) * 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
KR102000141B1 (ko) 2011-10-27 2019-07-15 웰스테이트 옵탈믹스 코퍼레이션 간상세포 유래 원추세포 생존능 인자를 인코딩하는 벡터
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
WO2014060517A1 (en) * 2012-10-17 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd)
PT3027646T (pt) 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
JP6684343B2 (ja) 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
US10857240B2 (en) 2016-01-05 2020-12-08 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP3526238A4 (en) 2016-10-11 2020-04-29 Wellstat Ophthalmics Corporation FUSION PROTEIN BETWEEN A SHORT-ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE
JP7495756B2 (ja) * 2019-12-09 2024-06-05 北京中因科技有限公司 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体
WO2026072752A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2010029130A1 (en) 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof

Similar Documents

Publication Publication Date Title
JP2005502319A5 (https=)
ES2577532T3 (es) Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune
CA2443345A1 (en) Disease-associated protein
CN115925928A (zh) 炎性疾病中的il-18结合蛋白(il-18bp)
UA127402C2 (uk) Моноклональне антитіло, яке специфічно зв'язується з людським pcsk9
CN102112154A (zh) IL-1α抗体及使用方法
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
US8946382B2 (en) Apelin peptides and methods of use
WO2021233433A1 (zh) 抗SARS-CoV-2刺突蛋白单克隆抗体
CA2923160A1 (en) Immune system modulators
JP2007525183A5 (https=)
CN116615221A (zh) 用于治疗细胞因子释放综合征和细胞因子风暴相关病症的靶向il-2、il-9和il-15信号传导的拮抗肽
CA2020700A1 (en) Compositions for the inhibition of protein hormone formation and uses thereof
JP2914672B2 (ja) Ｂｓｆ▲下２▼アンタゴニスト
JP2009526552A5 (https=)
CN101891815B (zh) Ck19单克隆抗体、其制备方法及用途
JP4592756B2 (ja) 高分子形マンノース結合型レクチンの大量生産方法
Cheng et al. House dust mite–induced sensitivity in mice
WO2021238854A1 (zh) 抗SARS-CoV-2刺突蛋白的单克隆抗体及其制备方法和用途
US8354106B2 (en) Antibodies against HMGB1 and fragments thereof
JP2005503113A5 (https=)
EP1451220A2 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
FR2855971B1 (fr) Analogues peptidiques comprenant au moins un residu aza-beta3-aminoacyle, et leurs utilisations, notamment en therapie
CN102775470B (zh) 一种抑制人乙型肝炎病毒感染的短肽及其应用